Practice trends in the treatment of actinic keratosis in the United States: 0.5% fluorouracil and combination cryotherapy plus fluorouracil are underused despite evidence of benefit

Journal of Cutaneous Medicine and Surgery

Volumn 16, Issue 2, 2012, Pages 107-114

  Hagele, Thomas J ^a   Levender, Michelle M ^a   Davis, Scott A ^a   Williford, Phillip M ^a   Feldman, Steven R ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL;

ACTINIC KERATOSIS; ADULT; AFRICAN AMERICAN; AGE DISTRIBUTION; AGED; ARTICLE; ASIAN; CHILD; CLINICAL PRACTICE; CONTROLLED STUDY; COST MINIMIZATION ANALYSIS; CROSS-SECTIONAL STUDY; CRYOTHERAPY; DERMATOLOGIST; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG TOLERABILITY; ETHNIC DIFFERENCE; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PATIENT COMPLIANCE; PHYSICIAN ATTITUDE; PRECANCER; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; SCHOOL CHILD; SEX DIFFERENCE; TREND STUDY; UNITED STATES;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES; CHILD; COMBINED MODALITY THERAPY; CRYOTHERAPY; FEMALE; FLUOROURACIL; HUMANS; KERATOSIS, ACTINIC; LINEAR MODELS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; TREATMENT OUTCOME; UNITED STATES;

EID: 84860330203     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.2310/7750.2011.11002     Document Type: Article

References (34)

1. Skin cancer. National Cancer Institute. Available at: http://www. cancer.gov/cancertopics/types/skin (accessed November 2011).
2. Callen JP, Bickers DR, Moy RL. Actinic keratoses. J Am Acad Dermatol 1997;36:650-3, doi:10.1016/S0190-9622(97)70265-2. (Pubitemid 27164509)
3. Dinehart SM, Nelson-Adesokan P, Cockerell C, et al. Metastatic cutaneous squamous cell carcinoma derived from actinic keratosis. Cancer 1997;79:920-3, doi:10.1002/(SICI)1097-0142(19970301) 79:5,920::AID-CNCR8.3.0.CO;2-F.
4. Moy RL. Clinical presentation of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000;42:8-10, doi:10.1067/ mjd.2000.103343.
5. Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol 2000;42:23-4, doi:10.1067/mjd.2000.103339.
6. Moller R, Reymann F, Hou-Jensen K. Metastases in dermatological patients with squamous cell carcinoma. Arch Dermatol 1979;115: 703-5, doi:10.1001/archderm.1979.04010060011017. (Pubitemid 9249657)
7. Smith ES, Feldman SR, Fleischer AB Jr, et al. Characteristics of office-based visits for skin cancer. Dermatologists have more experience than other physicians in managing malignant and premalignant skin conditions. Dermatol Surg 1998;24:981-5, doi:10.1016/S1076-0512(98)00095-8. (Pubitemid 28453046)
8. Feldman SR, Fleischer AB Jr, Williford PM, Jorizzo JL. Destructive procedures are the standard of care for treatment of actinic keratoses. J Am Acad Dermatol 1999;40:43-7, doi:10.1016/S0190- 9622(99)70526-8.
9. Graham GF. Advances in cryosurgery during the past decade. Cutis 1993;52:365-72. (Pubitemid 23355381)
10. Jorizzo J, Stewart D, Bucko A, et al. Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1-, 2-, or 4-week treatment in patients with actinic keratosis. Cutis 2002;70:335-9. (Pubitemid 41757441)
11. McIntyre WJ, Downs MR, Bedwell SA. Treatment options for actinic keratoses. Am Fam Physician 2007;76:667-71.
12. Balkrishnan R, Cayce KA, Kulkarni AS, et al. Predictors of treatment choices and associated outcomes in actinic keratoses: results from a national physician survey study. J Dermatolog Treat 2006;17:162-6, doi:10.1080/ 09546630600765081. (Pubitemid 44147835)
13. Loven K, Stein L, Furst K, Levy S. Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther 2002;24:990-1000, doi:10.1016/S0149-2918(02)80012-1. (Pubitemid 34734743)
14. Jorizzo JL, Carney PS, Ko WT, et al. Fluorouracil 5% and 0.5% creams for the treatment of actinic keratosis: equivalent efficacy with a lower concentration and more convenient dosing schedule. Cutis 2004;74:18-23. (Pubitemid 40125973)
15. Levy S, Furst K, Chern W. A pharmacokinetic evaluation of 0.5% and 5% fluorouracil topical cream in patients with actinic keratosis. Clin Ther 2001;23:908-20, doi:10.1016/S0149-2918 (01)80078-3.
16. Kaur RR, Alikhan A, Maibach HI. Comparison of topical 5-fluorouracil formulations in actinic keratosis treatment. J Dermatolog Treat 2010;21:267-71, doi:10.3109/095466309 03341937.
17. Weinstock MA, Bingham SF, Cole GW, et al. Reliability of counting actinic keratoses before and after brief consensus discussion: the VA Topical Tretinoin Chemoprevention (VATTC) trial. A novel 0.5% fluorouracil cream is minimally absorbed into the systemic circulation yet is as effective as 5% fluorouracil cream. Arch Dermatol 2001;137:1055-8.
18. Yentzer BA, Ade RA, Fountain JM, et al. Simplifying regimens promotes greater adherence and outcomes with topical acne medications: a randomized controlled trial. Cutis 2010;86:103-8.
19. Gupta AK. The management of actinic keratoses in the United States with topical fluorouracil: a pharmacoeconomic evaluation. Cutis 2002;70:30-6.
20. Jorizzo J, Weiss J, Furst K, et al. Effect of a 1-week treatment with 0.5% topical fluorouracil on occurrence of actinic keratosis after cryosurgery: a randomized, vehicle-controlled clinical trial. Arch Dermatol 2004;140:813-6, doi:10.1001/archderm.140.7.813. (Pubitemid 38917849)
21. Jorizzo J, Weiss J, Vamvakias G. One-week treatment with 0.5% fluorouracil cream prior to cryosurgery in patients with actinic keratoses: a double-blind, vehicle-controlled, long-term study. J Drugs Dermatol 2006;5:133-9.
22. Lee AD, Jorizzo JL. Optimizing management of actinic keratosis and photodamaged skin: utilizing a stepwise approach. Cutis 2009; 84:169-75.
23. Fleischer AB Jr, Feldman SR, Bradham DD. Office-based physician services provided by dermatologists in the United States in 1990. J Invest Dermatol 1994;102:93-7, doi:10.1111/1523-1747. ep12371739.
24. Fleischer AB Jr, Feldman SR, White RE, et al. Procedures for skin diseases performed by physicians in 1993 and 1994: analysis of data from the National Ambulatory Medical Care Survey. J Am Acad Dermatol 1997;37:719-24, doi:10.1016/S0190-9622(97)70107-5. (Pubitemid 27500314)
25. Aliotta SL, Vlasnik JJ, Delor B. Enhancing adherence to long-term medical therapy: a new approach to assessing and treating patients. Adv Ther 2004;21:214-31, doi:10.1007/BF02850154. (Pubitemid 39524899)
26. Vermeire E, Hearnshaw H, Van Royen P, Denekens J. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther 2001;26:331-42, doi:10.1046/j.1365-2710.2001.00363.x. (Pubitemid 32989555)
27. Bender BG, Rand C. Medication non-adherence and asthma treatment cost. Curr Opin Allergy Clin Immunol 2004;4:191-5, doi:10.1097/00130832-200406000- 00009. (Pubitemid 38685520)
28. Feldman SR, Camacho FT, Krejci-Manwaring J, et al. Adherence to topical therapy increases around the time of office visits. J Am Acad Dermatol 2007;57:81-3, doi:10.1016/j.jaad.2007.04.005. (Pubitemid 46908856)
29. Krejci-Manwaring J, Tusa MG, Carroll C, et al. Stealth monitoring of adherence to topical medication: adherence is very poor in children with atopic dermatitis. J Am Acad Dermatol 2007;56:211-6, doi:10.1016/j.jaad.2006.05.073. (Pubitemid 46074250)
30. Wilson R, Camacho F, Clark AR, et al. Adherence to topical hydrocortisone 17-butyrate 0.1% in different vehicles in adults with atopic dermatitis. J Am Acad Dermatol 2009;60:166-8, doi:10.1016/j.jaad.2008.09.031.
31. Yentzer B, Hick J, Williams L, et al. Adherence to a topical regimen of 5-fluorouracil, 0.5%, cream for the treatment of actinic keratoses. Arch Dermatol 2009;145:203-5, doi:10.1001/archdermatol. 2008.562.
32. Feldman SR. Practical ways to improve patients' treatment outcomes. Winston Salem (NC): Medical Quality Enhancement Corporation; 2009.
33. Feldman SR. Approaching psoriasis differently: patient-physician relationships, patient education and choosing the right topical vehicle. J Drugs Dermatol 2010;9:908-11.
34. Paiva EF, Rocha AT. [How to implement a guideline from theory to practice: the example of the venous thromboembolism prophylaxis]. Acta Med Port 2009;22:21-32.